People: use cases, players, stakeholders.
Eight regulatory triggers that demand validated bioanalysis · the five player categories that run the field · who decides, who pays, who is liable.
Use cases: what BMV is actually for.
Eight regulatory triggers that demand validated bioanalysisBMV can begin as analytical science, but in submission use it becomes regulated evidence work. The trigger determines the method scope, documentation depth, review pathway, and the inspection questions likely to follow the data.
PK supporting BE.
Generic sponsor triggers. ANDA / ANDE pathways depend on BE data integrity. The original use case that funded the entire bioanalytical CRO industry.
First-in-human FIH.
Early clinical studies need PK / PD baselines that can support dose-escalation and safety decisions. ISR and reproducibility expectations should be planned against the assay type, study purpose, and applicable guidance.
Biomarker qualification.
Biomarker assays need a defined context of use before validation depth can be judged. When a biomarker becomes decision-informing or registrational, method evidence and interpretation boundaries become more important.
Reference standard characterisation.
Reference materials and internal standards need controlled identity, lot history, storage, and suitability records. The evidence question is not only analytical performance; it is whether the material record supports continued method use.
Assay transfer.
Sponsor lab → CRO, CRO → CRO, or site-to-site movement creates a comparability question. The transfer record should show what changed, what stayed equivalent, and what partial validation or cross-validation was performed.
DBS & microsampling.
Microsampling can support paediatric, decentralised, or population PK designs, but it adds method-specific questions such as haematocrit effect, extraction recovery, sample stability, and matrix comparability.
Biosimilar PK.
Comparative PK against reference. Immunogenicity assay validation under ADA framework (M10 §7). Distinct from small-molecule. Biologic sponsor triggers.
Post-approval method transfer.
Manufacturing scale-up, formulation change. Type I / II variation support. Ongoing pharma sponsor trigger across the product lifecycle.
Source anchors: ICH M10 Step 4 guideline · FDA ICH M10 guidance page · FDA 2018 BMV guidance page. Company examples are ecosystem examples, not endorsements.
Big players: who runs the field.
CROs · pharma · regulators · tech · academiaThe bioanalytical ecosystem has five player categories. Sponsors set the strategy and pay; CROs execute most validations; regulators define the surface; tech vendors own the instruments; academia supplies the foundational science and the early-career talent.
Stakeholders: interests & leverage.
Who decides · who pays · who is affectedEach stakeholder in a bioanalytical programme has a distinct interest and a distinct lever. Reading the politics of a study correctly means knowing whose lever fires when the trial is challenged.
Source register.
official anchors · interpretation kept separateThis bioanalytical page uses official guidance as the source layer and separates iFeed interpretation from regulator text. Jurisdiction-specific details should be checked against the current regulator page before use in submissions, audits, or public checklists.
ICH M10 EU page.
EMA ICH M10 scientific guideline. Earlier EMA BMV guidance should be marked as historical where used for comparison.